This suggests that the level of NLRP3 activation during Plasmodium infection influences CM progression, and that targeting the NLRP3 inflammasome to reduce its activation could be an excellent pharmacological strategy for treating CM. This evidence concerns the gene NLRP3 and cutaneous mastocytosis.